S Chabot, N Dizeyi, L Ramnemark et al
Department of Translational Medicine, Urologic Research, Lund University, Malmo, Sweden.
Background Cernitin pollen extracts (brand name Cernilton) alleviates symptoms related to common lower uro-genital tract disorders in men. The underlying mechanisms are ill-defined but the inflammatory pathway could be one of them. In a previous in vitro study it was shown that Cernitin induce a regulatory effect on inflammatory parameters.
Methods In this study, male Sprague Dawley rats were used to validate the effects of Cernitin in chronic prostatitis and benign prostatic hyperplasia. Pain was assessed by von Frey assay.
Results Cernitin exhibited significant pain relief in the induced prostatitis rat model and was associated with a significant decrease in the intraprostatic level of COX-2 and MCP-1 in the prostatic tissue homogenates. In a parallel study, Cernitin treatment led to a significant decrease in prostate weight in rats with testosterone induced BPH. Concurrently, a significant decrease in the percentage of proliferation marker, Ki-67, and androgen receptor expressing cells was observed. Similarly, a low level of cytoplasmic 5alpha-reductase expression was observed in Cernitin- and finasteride-treated animals.
Conclusion The current in vivo experiments support the use of Cernitin as an anti-inflammatory and symptom reducing agent that could, in part, explain the impact of Cernitin on the management of chronic pelvic pain in men.
BIOSEB Instruments Used:
Von Frey Filaments (Bio-VF-M)